Journal Article
. 2011 Oct;13(5).
doi: 10.1186/bcr3038.

Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

Rachel C Jankowitz 1 Kristine Cooper  Mark G Erlander  Xiao-Jun Ma  Nicole C Kesty  Hongying Li  Mamatha Chivukula  Adam Brufsky  
Affiliations
  • PMID: 21999244
  •     24 References
  •     16 citations

Abstract

Introduction: Breast Cancer Index (BCI) combines two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene molecular grade index (MGI), that assess estrogen-mediated signalling and tumor grade, respectively. BCI stratifies early-stage estrogen-receptor positive (ER+), lymph-node negative (LN-) breast cancer patients into three risk groups and provides a continuous assessment of individual risk of distant recurrence. Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO).

Methods: Tumor samples from 265 ER+LN- tamoxifen-treated patients were identified from a single academic institution's cancer research registry. The BCI assay was performed and scores were assigned based on a pre-determined risk model. Risk was assessed by BCI and AO and correlated to clinical outcomes in the patient cohort.

Results: BCI was a significant predictor of outcome in a cohort of 265 ER+LN- patients (median age: 56-y; median follow-up: 10.3-y), treated with adjuvant tamoxifen alone or tamoxifen with chemotherapy (32%). BCI categorized 55%, 21%, and 24% of patients as low, intermediate and high-risk, respectively. The 10-year rates of distant recurrence were 6.6%, 12.1% and 31.9% and of breast cancer-specific mortality were 3.8%, 3.6% and 22.1% in low, intermediate, and high-risk groups, respectively. In a multivariate analysis including clinicopathological factors, BCI was a significant predictor of distant recurrence (HR for 5-unit increase = 5.32 [CI 2.18-13.01; P = 0.0002]) and breast cancer-specific mortality (HR for a 5-unit increase = 9.60 [CI 3.20-28.80; P < 0.0001]). AO was significantly associated with risk of recurrence. In a separate multivariate analysis, both BCI and AO were significantly predictive of outcome. In a time-dependent (10-y) ROC curve accuracy analysis of recurrence risk, the addition of BCI+AO increased predictive accuracy in all patients from 66% (AO only) to 76% (AO+BCI) and in tamoxifen-only treated patients from 65% to 81%.

Conclusions: This study validates the prognostic performance of BCI in ER+LN- patients. In this characteristically low-risk cohort, BCI classified high versus low-risk groups with ~5-fold difference in 10-year risk of distant recurrence and breast cancer-specific death. BCI and AO are independent predictors with BCI having additive utility beyond standard of care parameters that are encompassed in AO.

Multivariate continuation ratio models: connections and caveats.
P J Heagerty, S L Zeger.
Biometrics, 2000 Sep 14; 56(3). PMID: 10985208
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
P-L Jerevall, X-J Ma, +9 authors, O Stål.
Br J Cancer, 2011 May 12; 104(11). PMID: 21559019    Free PMC article.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
Survival model predictive accuracy and ROC curves.
Patrick J Heagerty, Yingye Zheng.
Biometrics, 2005 Mar 02; 61(1). PMID: 15737082
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Xiao-Jun Ma, Susan G Hilsenbeck, +6 authors, Mark G Erlander.
J Clin Oncol, 2006 Sep 30; 24(28). PMID: 17008703
First--select the target: better choice of adjuvant treatments for breast cancer patients.
A Goldhirsch, A S Coates, +4 authors, St Gallen Expert Panel Members.
Ann Oncol, 2006 Oct 31; 17(12). PMID: 17071934
Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
Lars E Rutqvist, Hemming Johansson, Stockholm Breast Cancer Study Group.
Acta Oncol, 2007 Apr 25; 46(2). PMID: 17453361
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Christine Desmedt, Fanny Piette, +18 authors, TRANSBIG Consortium.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545524
Highly Cited.
The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
Zuncai Wang, Sonika Dahiya, +6 authors, Dennis C Sgroi.
Clin Cancer Res, 2007 Nov 03; 13(21). PMID: 17975144
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Xiao-Jun Ma, Ranelle Salunga, +8 authors, Dennis Sgroi.
Clin Cancer Res, 2008 May 03; 14(9). PMID: 18451222
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Abenaa M Brewster, Gabriel N Hortobagyi, +8 authors, Francisco J Esteva.
J Natl Cancer Inst, 2008 Aug 13; 100(16). PMID: 18695137    Free PMC article.
Highly Cited.
An ideal prognostic test for estrogen receptor-positive breast cancer?
Soonmyung Paik, Gong Tang, Debora Fumagalli.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678837
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Comparison of prognostic gene expression signatures for breast cancer.
Benjamin Haibe-Kains, Christine Desmedt, +6 authors, Christos Sotiriou.
BMC Genomics, 2008 Aug 23; 9. PMID: 18717985    Free PMC article.
Gene expression profiling of breast cancer.
Ting Bao, Nancy E Davidson.
Adv Surg, 2008 Oct 29; 42. PMID: 18953822    Free PMC article.
Review.
Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
Elissa M Ozanne, Dejana Braithwaite, +3 authors, Jeffrey Belkora.
J Clin Oncol, 2008 Dec 03; 27(2). PMID: 19047286
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
New developments in hormone receptor-positive disease.
Martine J Piccart-Gebhart.
Oncologist, 2011 Feb 10; 16 Suppl 1. PMID: 21278440
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.
Maria B Lyng, Anne-Vibeke Lænkholm, +4 authors, Henrik J Ditzel.
PLoS One, 2013 Jan 24; 8(1). PMID: 23342080    Free PMC article.
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Laurel A Habel, Lori C Sakoda, +6 authors, Charles P Quesenberry.
Breast Cancer Res, 2013 Mar 19; 15(2). PMID: 23497539    Free PMC article.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.
E Laas, P Mallon, +7 authors, F Reyal.
Br J Cancer, 2015 Jan 16; 112(5). PMID: 25590666    Free PMC article.
Multigene prognostic tests in breast cancer: past, present, future.
Balázs Győrffy, Christos Hatzis, +3 authors, Lajos Pusztai.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848861    Free PMC article.
Highly Cited. Review.
Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.
Dominic A Pearce, Laura M Arthur, +6 authors, Andrew H Sims.
Sci Rep, 2016 Jul 08; 6. PMID: 27384960    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Flora Stavridi, Konstantine T Kalogeras, +19 authors, George Fountzilas.
PLoS One, 2016 Oct 04; 11(10). PMID: 27695115    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
Huajie Liu, Bin Liu, +9 authors, Qi Pang.
J Neurooncol, 2017 Mar 23; 132(3). PMID: 28321704
Endocrine Therapy for Early Breast Cancer: Updated Review.
Alexander Tremont, Jonathan Lu, John T Cole.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230126    Free PMC article.
Review.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
Genes and functions from breast cancer signatures.
Shujun Huang, Leigh Murphy, Wayne Xu.
BMC Cancer, 2018 Apr 28; 18(1). PMID: 29699511    Free PMC article.
Endocrine Therapy in Early Breast Cancer.
Katja Krauss, Elmar Stickeler.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982643    Free PMC article.
Review.